News Room
Technophage once again classified as ‘PME líder’
Technophage has been awarded by IAPMEI (Agency for Competitiveness and Innovation) with the distinction of 'PME líder'. This certification...
TechnoPhage announces U.S. FDA clearance of IND application to initiate clinical trial
U.S. FDA has just cleared the IND application of bacteriophage cocktail TP-102 to initiate Phase I/IIa clinical trial. TP-102 is a cocktail of five...
Technophage among companies with higher investment in R&D
In 2019, Technophage was among the top 100 companies with the highest R&D investment in Portugal. According to the provisional results of...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology